Forat Lutfi

Dr. Forat Lutfi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2020 in Neuro-Oncology
Verified
Journal Article
Closed access
NHNoa G Holtzman
Noa G Holtzman
HXHao Xie
Hao Xie
SBSoren Bentzen
Soren Bentzen
VKVivek Kesari
Vivek Kesari
ABAli Bukhari
Ali Bukhari
SDSaurabh Dahiya
Saurabh Dahiya
Background: CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associated neurotoxicity syndrome (ICANS), is poorly understood. To better elucidate the clinical characteristics, treatment outcomes, and correlative biomarkers of ICANS, we review here a single-center analysis of ICANS after CAR T-cell therapy in R/R LBCL.Methods: Patients (n = 45) with R/R LBCL treated with axicabtagene ciloleucel (axi-cel) were identified. Data regarding treatment course, clinical outcomes, and correlative studies were collected. Patients were monitored and graded for ICANS via CARTOX-10 scoring and Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria, respectively.Results: Twenty-five (56%) patients developed ICANS, 18 (72%) of whom had severe (CTCAE grades 3–4) ICANS. Median time to development of ICANS was 5 days (range, 3–11). Elevated pre-infusion (day 0 [D0]) fibrinogen (517 vs 403 mg/dL, upper limit of normal [ULN] 438 mg/dL, P = 0.01) and D0 lactate dehydrogenase (618 vs 506 units/L, ULN 618 units/L, P = 0.04) were associated with ICANS. A larger drop in fibrinogen was associated with ICANS (393 vs 200, P < 0.01). Development of ICANS of any grade had no effect on complete remission (CR), progression-free survival (PFS), or overall survival (OS). Duration and total dose of steroid treatment administered for ICANS did not influence CR, PFS, or OS.Conclusions: ICANS after CAR-T with axi-cel for R/R LBCL was seen in about half of patients, the majority of which were high grade. Contrary to previous reports, neither development of ICANS nor its treatment were associated with inferior CR, PFS, or OS. The novel finding of high D0 fibrinogen level can identify patients at higher risk for ICANS.

9 September 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
FLForat Lutfi
Forat Lutfi
NHNoa G. Holtzman
Noa G. Holtzman
AKAnkit J. Kansagra
Ankit J. Kansagra
MAMoaath Mustafa Ali
Moaath Mustafa Ali
ABAli Bukhari
Ali Bukhari
SDSaurabh Dahiya
Saurabh Dahiya

10 November 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
FLForat Lutfi
Forat Lutfi
NHNoa Holtzman
Noa Holtzman
JSJonathan Siglin
Jonathan Siglin
ABAli Bukhari
Ali Bukhari
MAMoaath Mustafa Ali
Moaath Mustafa Ali
SDSaurabh Dahiya
Saurabh Dahiya
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

1 March 2020 in Hematology/Oncology and Stem Cell Therapy
Verified
Journal Article
Open access
FLForat Lutfi
Forat Lutfi
WIWilliam Paul Skelton Iv
William Paul Skelton Iv
YWYu Wang
Yu Wang
EREmma Rosenau
Emma Rosenau
NFNosha Farhadfar
Nosha Farhadfar
MNMaxim Norkin
Maxim Norkin
Objective/background: Clinical predictors of delayed engraftment following autologous hematopoietic cell transplantation (AHCT) are poorly described in the literature. The purpose of this study was to identify pretransplant characteristics contributing to delayed engraftment (DE) following AHCT. Methods: A retrospective, single institution study of 1162 consecutive patients undergoing AHCT from January 1996 to August 2016 was studied for DE. DE was defined as platelet count ≤ 50,000/μl, hemoglobin ≤ 8 g/dL, or absolute neutrophil count ≤ 1000/mm 3 . Results: Of the 1162 AHCT recipients, 263 (22.6%) were identified as having DE at 30-days post-AHCT with 80.0% being solely due to delayed platelet engraftment. Patients with Non-Hodgkin lymphoma (NHL) represented 18% of the original cohort, but accounted for 45% of those with DE, whereas multiple myeloma patients represented 59% of the initial cohort, but only 29% of those that had DE. At 3 months post-AHCT, transfusion dependence ( p = .0083) prior to AHCT, low-infused CD34 + cell dose < 3 × 10 6 /kg ( p = .0012), and low preAHCT platelet count < 150 × 10 3 /μL ( p = .0027) were significantly associated with delayed engraftment. Conclusion: Transfusion dependence prior to AHCT, pre-AHCT platelet count, and CD34 + cell dose were the strongest predictors of delayed engraftment in patients undergoing AHCT.

19 June 2023 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Open access
FLForat Lutfi
Forat Lutfi
OGOlga Goloubeva
Olga Goloubeva
AKAmer Kowatli
Amer Kowatli
AGAnton Gryaznov
Anton Gryaznov
DKDong W Kim
Dong W Kim
SDSaurabh Dahiya
Saurabh Dahiya
CD19 directed CAR-T therapy for Large B-cell lymphoma (LBCL) has shown great therapeutic response in patients with relapsed/refractory disease with response rates of 60-80%. However, in patients with a partial response (PR) on initial day 28 post CAR-T therapy imaging, clinical uncertainty remains as half of these patients will ultimately have relapsed disease. PATIENTS: In 24 patients receiving CD19 directed CAR-T therapy for relapsed/refractory LBCL achieving a PR on day 28, we utilize imaging biomarkers by 18F-FDG PET/CT imaging at pre CAR-T therapy baseline and day 28 to determine factors that may predict best overall response (B-OR), progression free survival (PFS), and overall survival (OS). METHODS: Out of 75 patients receiving CAR-T therapy at a single institution, we retrospectively identified and reviewed 25 (33%) as achieving a PR on day 28. PR was defined using the 2014 Lugano classification system. All patients received standard of care CD19 directed CAR-T therapy with axicabtagene ciloleucel. Two independent nuclear medicine physicians measured baseline (pre-CAR-T therapy) and day 28 PET/CT SUVmax, SUVmean and TMV (cm3) of each lesion (node, organ or marrow uptake, if any) using ROVER software. All statistical tests were two-sided and conducted at the 0.05 level of significance. R version 1.3.1099 (R-studio) was used for statistical modeling. CONCLUSION: We demonstrate that a higher day 28 SUVmax was significantly higher in those with a B-OR of PR and in our modeling, a lower day 28 SUVmax may predict favorable PFS and OS. Additionally, lower TMV, both at baseline and day 28, may also be predictive of longer PFS and OS, while lower TLG at baseline, but not day 28 is significantly associated with a B-OR of CR. While further study is warranted, these imaging biomarkers may allow for early identification of those with a day 28 PR at highest risk for relapse leading to early intervention to improve long term outcomes.

29 July 2020 in Cureus
Verified
Journal Article
Open access
PDF file
FLForat Lutfi
Forat Lutfi
ABAmin Benyounes
Amin Benyounes
NFNaveed Farrukh
Naveed Farrukh
JBJacqueline Bork
Jacqueline Bork
VDVu H. Duong
Vu H. Duong
Clinicians have continued to report on the clinical behavior and characteristics of patients with coronavirus disease 2019 (COVID-19) as our knowledge of the virus continues to mature. Herein, we report the case of a 39-year-old male with multiple comorbidities who became critically ill with COVID-19 infection, requiring mechanical ventilation and vasopressors, and then developed agranulocytosis following clinical improvement and resolution of symptoms of COVID infection. The period of agranulocytosis coincided with the development of thrombocytosis, and following resolution of agranulocytosis, the platelet count also normalized, suggesting a possible related mechanism. Interestingly, the patient was treated with TBO-filgrastim 480 mcg daily with a rapid reconstitution of neutrophils. While the mechanism of agranulocytosis remains unknown, we report, to our knowledge, the first known case of agranulocytosis following COVID-19 infection and its successful treatment with granulocyte colony-stimulating factor.